Blosozumab
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect. Blosozumab was developed by Eli Lilly and Company.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Blosozumab
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect. Blosozumab was developed by Eli Lilly and Company.
has abstract
Blosozumab binds SOST, a negat ...... oped by Eli Lilly and Company.
@en
بلوسوزوماب هو جسم مضاد وحيد النسيلة يدرب ليستخدم في علاج تخلخل العظم. طورته .
@ar
CAS number
1132758-87-2
FDA UNII code
83YOM0NEL5
KEGG
Wikipage page ID
33,052,058
page length (characters) of wiki page
Wikipage revision ID
997,368,801
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChemSpiderID
none
@en
KEGG
D10094
@en
mab type
mab
@en
source
zu/o
@en
target
type
mab
@en
Verifiedfields
changed
@en
verifiedrevid
457,463,532
Watchedfields
changed
@en
wikiPageUsesTemplate
subject
comment
Blosozumab binds SOST, a negat ...... oped by Eli Lilly and Company.
@en
بلوسوزوماب هو جسم مضاد وحيد النسيلة يدرب ليستخدم في علاج تخلخل العظم. طورته .
@ar
label
Blosozumab
@en
بلوسوزوماب
@ar